Jefferies Reiterates Buy on Bristol-Myers Squibb (BMY) Following a 2017 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Bristol-Myers Squibb (BMY) Enters Collaboration with JNJ's (JNJ) Janssen for Opdivo/Darzalex Combo
January 5, 2017 7:05 AM ESTBristol-Myers Squibb Company (NYSE: BMY) today announced a new clinical research collaboration with... More
Deutsche Bank to pay $95 million to end U.S. tax fraud case
January 4, 2017 4:10 PM ESTBy Nate Raymond and Jonathan Stempel
NEW YORK (Reuters) - Deutsche Bank AG agreed to pay $95 million to resolve a U.S. government lawsuit accusing the German bank of tax fraud for using "insolvent" shell companies to hide significant tax liabilities from the Internal Revenue Service in 2000.
Under the accord described in papers filed on Wednesday with the federal court in Manhattan, Deutsche Bank also admitted to trying to stick the shell companies with the tax bill for its then-new stake in drugmaker Bristol-Myers Squibb Co (NYSE:... More
Five Prime Therapeutics (FPRX) Says Bristol-Myers Squibb (BMY) Exercised Option to Extend Collaboration
January 4, 2017 4:08 PM ESTFive Prime Therapeutics, Inc. (Nasdaq: FPRX) announced that Bristol-Myers Squibb Company (NYSE: BMY) has exercised its option to extend the research term of its discovery collaboration agreement with Five Prime for the discovery, development and commercialization of immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways.
The original collaboration agreement was established in March 2014 and focused on two undisclosed immune checkpoint pathways. In January 2016, the companies added a third immune checkpoint pathway to the collaboration. Bristol-Myers... More
Goldman Expects Oncology M&A To Be Active In 2017, Sees (GILD), (JNJ), (PFE), (MRK), (NVS), (SNY), (LLY) As Possible Acquirers
January 4, 2017 6:40 AM ESTGoldman Sachs analyst Salveen Richter expect an M&A uptick in 2017, with cancer remaining a focus. Richter notes after a record year of BioPharma M&A in 2015 ($265bn in value), deal activity fell in the politically focused environment of 2016, with transaction values at ~50% of the prior year.
Potential acquirers: Gilead Sciences (NASDAQ: GILD), Johnson & Johnson... More
